The rise in the number of people aged 65 years and older living with inflammatory rheumatic
diseases such as rheumatoid arthritis is causing considerable challenges for clinicians. As …

Despite the improvement in treatment for people with RA,∼ 30% of patients remain
symptomatic in the presence of optimized medical therapy, described as having 'difficult-to …

Objective To assess polypharmacy in women and men with psoriatic arthritis (PsA). Methods
From the German BARMER health insurance database, 11 984 persons with PsA and …

Older individuals experience various noninflammatory and autoimmune inflammatory
rheumatic diseases. Given the increased incidence of rheumatic conditions in older adults, it …

Objectives This study aimed to clarify factors associated with polypharmacy among patients
with systemic lupus erythematosus. Methods This single-centre cross-sectional study was …

Rheumatoid arthritis (RA) is one of the most common rheumatic conditions, impacting quality
of life on several domains. Major breakthroughs have been achieved over the past three …

Objective: To assess polypharmacy and related medication aspects in Middle-European
rheumatoid arthritis (RA) patients, and to discuss the results in view of a systematic literature …

The world population is aging, and the rheumatology workforce must be prepared to care for
medically complex older adults. We can learn from our colleagues and experts in geriatrics …

Polypharmacy is increasingly common in rheumatology due to the complex nature of
managing chronic autoimmune diseases. To date there has been limited research into the …

Introduction The safety of tofacitinib in psoriatic arthritis (PsA) and rheumatoid arthritis (RA)
has been demonstrated in clinical studies of≤ 4 and 9.5 years, respectively. Post-marketing …